IL17A and obesity disorder: Evidence from the literature indicates that obesity adversely affects the clinical response to biological therapies in patients with psoriasis, with anti-IL-17 and anti-IL-23 therapies showing greater susceptibility to reduced efficacy in individuals with a higher BMI compared to anti-TNF agents.